The NIH is partnering with the U.S. Food and Drug Administration (FDA) and the Defense Advanced Research Projects Agency (DARPA) to advance the field of regulatory science, a specialized research area that aims to improve assessment of experimental therapies, preventives, and diagnostics. The Common Fund’s Regulatory Science program is fostering the development, evaluation and availability of new or improved tools, methods, standards, and applied science that support a better understanding and improved evaluation of product safety, quality, effectiveness, and manufacturing throughout the product life cycle.
During the initial phase of the program, launched in fiscal year 2010, four new research awards in high priority areas of regulatory science were supported. Expansion of the program in FY 2012 focuses on developing new cell-based technologies, called microsystems, to predict more accurately drug safety and efficacy in humans.
- NEW! 'Organs on a Chip' named a Top Ten Emerging Technology for 2016 by The World Economic Forum. Read about the full list in Scientific American.
- NIH Director's Blog: If I Only Had a Brain? Tissue Chips Predict Neurotoxicity
- Researchers Create Artificial Organs That Fit In Your Hand (NPR)
- In the New Yorker article: “Of Mice and Micro-Organs.”
- On WXXI News, read and listen to: “Human-on-a-chip” featuring MPS members from the NIH Center for Advancing Translational Sciences.
- In a special supplement to Volume 4 of the journal Stem Cell Research & Therapy.
- Vanderbilt’s neurovascular chip project moves into new phase
NEW: Funding Opportunities for the Continuation of Tissue Chip Research
The Tissues-on-Chips Consortium led by the National Center for Advancing Translational Sciences (NCATS) is soliciting applications for the Microphysiological Systems (MPS) for Disease Modeling and Efficacy Testing Program. The goal of this FOA is to promote the development of in vitro microphysiological systems in modeling human diseases that mimic the pathology in major human organs and tissues, and the use of these disease models to facilitate the assessment of biomarkers, bioavailability, efficacy, and toxicity of therapeutic agents prior to entry into clinical trials. Applications are now due December 13, 2016 (see NOT-TR-17-005). More information can be found here.
THE NIH AND THE CENTER FOR THE ADVANCEMENT OF SCIENCE IN SPACE (CASIS) share an interest in utilizing the unique microgravity environment of the ISS National Lab to conduct research using microphysiological systems as a means to study relevant diseases and disorders. To that end, NCATS has released an new FOA designed to leverage recent advances in tissue engineering and microfabrication to create microphysiological systems and organ-on-chip technology platforms that recapitulate human physiology under the extreme environment of space. Applications are due December 15, 2016. More information can be found here.
National Center for Advancing Translational Sciences (NCATS) site: Tissue Chip for Drug Screening program
Chip is an interactive model that can help you learn about the innovative developments from the Tissue Chip program.
For more information about the Tissue Chip program, watch the new video from the National Center for Advancing Translational Sciences (NCATS).